Haematologica (Aug 2024)
A phase II study of post-remission therapy with pembrolizumab in older patients with acute myeloid leukemia
- Kevin Quann,
- Konstantinos Lontos,
- Alison Sehgal,
- Anastasios Raptis,
- Annie Im,
- Robert L. Redner,
- Kathleen A. Dorritie,
- Mounzer Agha,
- Jing-Zhou Hou,
- Rafic Farah,
- James Rossetti,
- Daniel P. Normolle,
- Theresa L. Whiteside,
- Yen-Michael Sheng Hsu,
- Michael Boyiadzis
Affiliations
- Kevin Quann
- Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh PA; UPMC Hillman Cancer Center
- Konstantinos Lontos
- UPMC Hillman Cancer Center
- Alison Sehgal
- UPMC Hillman Cancer Center
- Anastasios Raptis
- UPMC Hillman Cancer Center
- Annie Im
- Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh PA; UPMC Hillman Cancer Center
- Robert L. Redner
- Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh PA; UPMC Hillman Cancer Center
- Kathleen A. Dorritie
- Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh PA; UPMC Hillman Cancer Center
- Mounzer Agha
- UPMC Hillman Cancer Center
- Jing-Zhou Hou
- UPMC Hillman Cancer Center
- Rafic Farah
- UPMC Hillman Cancer Center
- James Rossetti
- UPMC Hillman Cancer Center
- Daniel P. Normolle
- Department of Biostatistics, University of Pittsburgh School of Public Health
- Theresa L. Whiteside
- UPMC Hillman Cancer Center, Pittsburgh, PA; Department of Pathology, University of Pittsburgh School of Medicine
- Yen-Michael Sheng Hsu
- Immunologic Monitoring and Cellular Products Laboratory, UPMC Hillman Caner Center
- Michael Boyiadzis
- Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine
- DOI
- https://doi.org/10.3324/haematol.2024.285313
- Journal volume & issue
-
Vol. 999,
no. 1
Abstract
Not available.
